Business · 12/09/2014Updated: 10/17/2026 · 1 min read
FDA Announces Approval of Eye Tracking Study on Direct-to-Consumer Prescription Drug Advertisements
Summary
The Food and Drug Administration (FDA) has announced that it has received approval from the Office of Management and Budget (OMB) to conduct an eye tracking study on direct-to-consumer prescription drug advertisements, as required by the Paperwork Reduction Act of 1995.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →